Chemistry:Voxvoganan
From HandWiki
Voxvoganan (LTX-109, Lytixar) is an experimental antibiotic medication for topical use. It is a synthetic peptide which is in clinical trials against skin infections caused by drug-resistant strains of Staphylococcus aureus.[1][2][3][4][5][6]
References
- ↑ "A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption". Journal of Medicinal Chemistry 54 (16): 5786–5795. August 2011. doi:10.1021/jm200450h. PMID 21732630.
- ↑ "In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus". Antimicrobial Agents and Chemotherapy 56 (8): 4478–4482. August 2012. doi:10.1128/AAC.00194-12. PMID 22585222.
- ↑ "LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus aureus". Antimicrobial Agents and Chemotherapy 59 (1): 145–151. January 2015. doi:10.1128/AAC.03513-14. PMID 25331699.
- ↑ "Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications". Current Topics in Medicinal Chemistry 17 (5): 576–589. 2017. doi:10.2174/1568026616666160713130452. PMID 27411325.
- ↑ "Staphylococcus aureus nasal decolonization strategies: a review". Expert Review of Anti-Infective Therapy 17 (5): 327–340. May 2019. doi:10.1080/14787210.2019.1604220. PMID 31012332.
- ↑ "Antibacterials with Novel Chemical Scaffolds in Clinical Development". Drugs 85 (3): 293–323. January 2025. doi:10.1007/s40265-024-02137-x. PMID 39847315.
 |  |
